- <![CDATA[Poll Findings Highlight the Most Anticipated GU Cancer Abstracts at ASCO 2026]]><![CDATA[GU experts identified key abstracts of interest from the upcoming ASCO Annual Meeting via OncLive’s social media.]]>onclive · 2mo ago↗ source
- Aardvark's next move after clinical hold; Alumis' verdict on Acelyrin assetPlus, news about Tenaya’s TN-401 and Taiho’s Inqovi. 📉 Aardvark to unblind rare disease trial following clinical hold: The FDA has placed a full clinical hold on the company's candidate for ...Endpoints · 2mo ago↗ source
- <![CDATA[OncLive Polls Reveal Picks for Top GI Cancer Abstracts, Areas of Interest at ASCO 2026]]><![CDATA[Polls highlighted key abstracts of interest from the upcoming ASCO Annual Meeting.]]>onclive